Medication info
Candesartan 16 mg (Candesartan Cilexetil)

Candesartan 16 mg (Candesartan Cilexetil)

Prescription medicationTabletOral
Ingredient · strength
Candesartan Cilexetil›16mg / 1 tablet
Manufacturer / importer
Myungmoon Pharmaceutical Co., Ltd.
Appearance
Round tablets with a convex face, light yellowish-pink in color.
Packaging
30 tablets/bottle, 100 tablets/bottle, 30 tablets (10 tablets/PTP*3, for export)
Approval status
Active

MFDS item code 200907796 · Notified 2009.10.29 · Insurance code 649805020

Summary

Main use
Treatment of essential hypertension and heart failure with reduced left ventricular systolic function
Who takes it
Adults · Children
Adult dose
This medicine should be taken at the same time each day, with or without food. 1. Essential hypertension Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is not controlled with this dose, other treatment should be considered. The maximum effect occurs within 4 weeks of starting treatment. Elderly: No adjustment of the initial dose is necessary. Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful monitoring in patients at increased risk of hypotension, such as those with volume depletion. Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. Patients with hepatic impairment: The initial dose for patients with mild or moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, depending on the patient's tolerability. Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild ∼ moderate hepatic impairment: No adjustment of the initial dose is necessary.
Child dose
Essential hypertension: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. Heart failure: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Ingredients

Manufacturer
Myungmoon Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure with reduced left ventricular systolic function

  • Essential hypertension
  • heart failure
View approved original text

This medication is used to effectively manage blood pressure in patients with essential hypertension. It is also effective for heart failure patients with impaired left ventricular function who require additional treatment with ACE inhibitors or have poor tolerance. This helps to alleviate heart failure symptoms and improve cardiac function. Thus, it can be safely used for the management of hypertension and heart failure.

How to take

Adult dose

This medicine should be taken at the same time each day, with or without food. 1. Essential hypertension Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is not controlled with this dose, other treatment should be considered. The maximum effect occurs within 4 weeks of starting treatment. Elderly: No adjustment of the initial dose is necessary. Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful monitoring in patients at increased risk of hypotension, such as those with volume depletion. Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. Patients with hepatic impairment: The initial dose for patients with mild or moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, depending on the patient's tolerability. Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild ∼ moderate hepatic impairment: No adjustment of the initial dose is necessary.

Child dose

Essential hypertension: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. Heart failure: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Precautions

This medication poses a serious risk of harm to the fetus or newborn during pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. It should not be used by individuals allergic to this medication or its components, pregnant or breastfeeding women, patients with severe liver dysfunction, or patients with hereditary angioedema. Caution is advised for the elderly, patients with hyperkalemia, patients with mild liver function impairment, and patients with heart valve disease or obstructive cardiomyopathy. Mild side effects such as dizziness, back pain, and respiratory infections may occur during this medication's usage, and in rare cases, severe allergic reactions, renal function impairment, or hypotension may occur, necessitating immediate consultation with healthcare providers if symptoms arise. Especially, patients with heart failure or compromised renal function should regularly monitor potassium levels and renal function for any abnormalities. Caution is required during driving or operating machinery due to potential dizziness or fatigue resulting from blood pressure reduction. Combining this medication with other antihypertensives or potassium-sparing diuretics may increase the risk of side effects, so consultation with a healthcare provider is necessary before use. Women who are pregnant or planning to become pregnant should not use this medication, and it is advisable to avoid use while breastfeeding. Safety and efficacy for children and adolescents have not been established, so usage is not recommended in these groups. In the case of overdose, symptoms may include hypotension, dizziness, and tachycardia; appropriate treatment should be sought immediately at a medical institution. This medication should be stored out of reach of children and should not be transferred to another container.

Side effects

  • Dizziness
  • Back pain
  • Respiratory infection
  • Upper respiratory tract infection
  • Pharyngitis
  • Rhinitis
  • Asthenia
  • Fever
  • Abnormal sensation
  • Dyspepsia
Show 67 more
  • Gastritis
  • Tachycardia
  • Palpitations
  • Increased creatine kinase
  • Hyperglycemia
  • Hypertriglyceridemia
  • Hyperuricemia
  • Myalgia
  • Nosebleed
  • Anxiety
  • Depression
  • Somnolence
  • Dyspnea
  • Rash
  • Increased sweating
  • Hematuria
  • Hypotension
  • Hyperkalemia
  • Renal impairment
  • Increased creatinine
  • Increased urea
  • Fatigue
  • Peripheral edema
  • Chest pain
  • Headache
  • Bronchitis
  • Cough
  • Sinusitis
  • Nausea
  • Abdominal pain
  • Diarrhea
  • Vomiting
  • Arthralgia
  • Proteinuria
  • Leukopenia
  • Neutropenia
  • Agranulocytosis
  • Hyponatremia
  • Hypoglycemia
  • Seizures
  • Altered consciousness
  • Increased liver enzyme levels
  • Hepatitis
  • Jaundice
  • Urticaria
  • Pruritus
  • Angioedema
  • Rhabdomyolysis
  • Acute renal failure
  • Interstitial pneumonia
  • Shock
  • Syncope
  • Loss of consciousness
  • Paralysis
  • Hypertonia
  • Facial flushing
  • Weight gain
  • Facial edema
  • Thirst
  • Sleep disorder
  • Decreased libido
  • Memory loss
  • Anorexia
  • Increased appetite
  • Tinnitus
  • Taste disturbance
  • Erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is advisable to keep the storage temperature between 1 and 30 degrees Celsius. Storing it this way ensures the medication's efficacy is safely maintained.

Appearance and packaging

Appearance

Round tablets with a convex face, light yellowish-pink in color.

Package unit

30 tablets/bottle, 100 tablets/bottle, 30 tablets (10 tablets/PTP*3, for export)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.